Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients
In recent years, significant changes in stroke prophylaxis in patients with atrial fibrillation (AF) have been observed. Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used in the prevention of thromboembolic complications in patients with AF. The aim of the study was to eval...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/6657776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547744684703744 |
|---|---|
| author | B. Bielecka I. Gorczyca O. Jelonek B. Wożakowska-Kapłon |
| author_facet | B. Bielecka I. Gorczyca O. Jelonek B. Wożakowska-Kapłon |
| author_sort | B. Bielecka |
| collection | DOAJ |
| description | In recent years, significant changes in stroke prophylaxis in patients with atrial fibrillation (AF) have been observed. Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used in the prevention of thromboembolic complications in patients with AF. The aim of the study was to evaluate recommended stroke prophylaxis in patients with AF and to identify predictors of using NOACs in patients treated with anticoagulant therapy. The present study was a retrospective, observational, single-center study which included consecutively hospitalized patients in the reference cardiology center from January 2014 to December 2018. In the study group of 4027 patients with AF, to prevent thromboembolic complications, OACs were used in 3680 patients (91.4%), an antiplatelet drug(s) was used in 124 patients (3.1%), and 223 patients (5.5%) did not undergo any thromboembolic event prevention. In the group of 3680 patients treated with OACs, 2311 patients (62.8%) received NOACs and 1639 patients (37.2%), VKAs. Independent predictors of the use of NOACs were age (OR, 1.02; 95% CI, 1.01–1.03; P<0.001), a previous thromboembolic event (OR, 1.29; 95% CI, 1.01–1.65; P=0.04), nonpermanent AF (OR, 1.61; 95% CI, 1.34–1.93; P<0.001), and eGFR (OR, 1.22; 95% CI, 1.02–1.46; P=0.03). Between 2014 and 2018, an increase of patients treated with OACs, mainly with NOACs, was observed. Age, past thromboembolic complications, nonpermanent AF, and preserved renal function determined the choice of NOACs. |
| format | Article |
| id | doaj-art-e5dee122958a434697f74c7cc05c6c65 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-e5dee122958a434697f74c7cc05c6c652025-02-03T06:43:34ZengWileyCardiology Research and Practice2090-80162090-05972021-01-01202110.1155/2021/66577766657776Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation PatientsB. Bielecka0I. Gorczyca1O. Jelonek2B. Wożakowska-Kapłon31st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce 25-736, Poland1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce 25-736, Poland1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce 25-736, Poland1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce 25-736, PolandIn recent years, significant changes in stroke prophylaxis in patients with atrial fibrillation (AF) have been observed. Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used in the prevention of thromboembolic complications in patients with AF. The aim of the study was to evaluate recommended stroke prophylaxis in patients with AF and to identify predictors of using NOACs in patients treated with anticoagulant therapy. The present study was a retrospective, observational, single-center study which included consecutively hospitalized patients in the reference cardiology center from January 2014 to December 2018. In the study group of 4027 patients with AF, to prevent thromboembolic complications, OACs were used in 3680 patients (91.4%), an antiplatelet drug(s) was used in 124 patients (3.1%), and 223 patients (5.5%) did not undergo any thromboembolic event prevention. In the group of 3680 patients treated with OACs, 2311 patients (62.8%) received NOACs and 1639 patients (37.2%), VKAs. Independent predictors of the use of NOACs were age (OR, 1.02; 95% CI, 1.01–1.03; P<0.001), a previous thromboembolic event (OR, 1.29; 95% CI, 1.01–1.65; P=0.04), nonpermanent AF (OR, 1.61; 95% CI, 1.34–1.93; P<0.001), and eGFR (OR, 1.22; 95% CI, 1.02–1.46; P=0.03). Between 2014 and 2018, an increase of patients treated with OACs, mainly with NOACs, was observed. Age, past thromboembolic complications, nonpermanent AF, and preserved renal function determined the choice of NOACs.http://dx.doi.org/10.1155/2021/6657776 |
| spellingShingle | B. Bielecka I. Gorczyca O. Jelonek B. Wożakowska-Kapłon Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients Cardiology Research and Practice |
| title | Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients |
| title_full | Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients |
| title_fullStr | Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients |
| title_full_unstemmed | Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients |
| title_short | Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients |
| title_sort | trends in stroke prevention between 2014 and 2018 in hospitalized atrial fibrillation patients |
| url | http://dx.doi.org/10.1155/2021/6657776 |
| work_keys_str_mv | AT bbielecka trendsinstrokepreventionbetween2014and2018inhospitalizedatrialfibrillationpatients AT igorczyca trendsinstrokepreventionbetween2014and2018inhospitalizedatrialfibrillationpatients AT ojelonek trendsinstrokepreventionbetween2014and2018inhospitalizedatrialfibrillationpatients AT bwozakowskakapłon trendsinstrokepreventionbetween2014and2018inhospitalizedatrialfibrillationpatients |